Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
8.28
-0.30 (-3.50%)
At close: May 22, 2026, 4:00 PM EDT
8.25
-0.03 (-0.36%)
After-hours: May 22, 2026, 4:10 PM EDT

Xilio Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
53.4843.776.34---
Revenue Growth (YoY)
476.71%589.88%----
Gross Profit
53.4843.776.34---
Selling, General & Admin
28.1229.7124.782729.9523.86
Research & Development
67.6156.0441.2152.1459.251.19
Other Operating Expenses
--0.94---
Total Operating Expenses
95.7385.7566.9379.1389.1575.04
Operating Income
-42.24-41.98-60.58-79.13-89.15-75.04
Other Non-Operating Income (Expense)
10.026.952.342.730.93-0.76
Total Non-Operating Income (Expense)
10.946.952.342.730.93-0.76
Pretax Income
-31.3-35.04-58.24-76.4-88.22-75.8
Net Income
-31.3-35.04-58.24-76.4-88.22-75.8
Net Income to Common
-31.3-35.04-58.24-76.4-88.22-75.8
Shares Outstanding (Basic)
1184220
Shares Outstanding (Diluted)
1284220
Shares Change (YoY)
149.03%118.70%94.61%0.38%388.59%970.34%
EPS (Basic)
-3.40-4.19-15.24-38.92-45.08-189.28
EPS (Diluted)
-3.55-4.19-15.24-38.92-45.08-189.28
Shares Outstanding
5.784.533.271.971.961.95
Free Cash Flow
-57.37-5.51-18.41-69.11-77.59-81.85
Free Cash Flow Per Share
-4.95-0.66-4.82-35.19-39.66-204.40
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-84.46%-95.92%-954.95%---
Profit Margin
-64.00%-80.05%-918.05%---
FCF Margin
-107.26%-12.59%-290.26%---
EBITDA
-43.78-40.44-58.94-77.23-87.3-73.55
EBITDA Margin
-81.86%-92.40%-929.03%---
EBIT
-42.24-41.98-60.58-79.13-89.15-75.04
EBIT Margin
-84.46%-95.92%-954.95%---
Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q